Pfizer settles hormone-drug suit after $72.6M jury award

Pfizer ($PFE) has settled a legal dispute with three hormone-drug patients who won $72.6 million in compensatory damages this week. The lawsuit, which claimed that menopause drugs caused the women's breast cancer, had been scheduled for a punitive-damages hearing beginning today.

Pfizer agreed to wrap up the dispute with Susan Elfont, Bernadette Kalenkoski and Judy Mulderig, after a jury awarded each of them more than $20 million in compensation, Bloomberg reports. "The parties have entered into a mutual agreement to resolve this case under confidential terms," spokesman Chris Loder told the news service.

The terms of the settlement weren't disclosed. Ted Meadows, a lawyer representing the three women, said, "They're just glad to be able to go on with their lives."

Separately, the Pennsylvania Supreme Court agreed to review Pfizer's argument against $8.6 million in damages awarded in another hormone-drug case. The company has set aside $772 million to cover claims involving its Wyeth unit's estrogen drug Premarin, its Upjohn unit's progestin med Provera, and the combination pill Prempro.

- read the Bloomberg coverage

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.